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The one-day symposium „New Diagnostic Trends in 
Early Detection of Oncological and Rare Diseases” was 
held at the Ruđer Bošković Institute, Zagreb on April 17, 
2018. The symposium was organised by the Croatian 
Society of Biochemistry and Molecular Biology and the 
Slovenian Biochemistry Society, with the Organising 
Committee comprising Tatjana Marčac Grahek, Zrinka 
Kovarik, Tihomir Balog, and Janko Kos. The aim was to 
inform the scientific community on developments and new 
perspectives in biomolecular life sciences arising from 
advancements in methodology. The symposium comprised 
lectures given by eminent researchers devoted to diagnostic 
and early detection of oncological and rare diseases. 
Tremendous advancements in methodology, such as next-
generation sequencing technology, have transformed 
biological and biomedical research, providing a platform 
that drives genetic analysis at unprecedented rates. The 
symposium undoubtedly provided an excellent opportunity 
to exchange ideas and experiences with researchers and 
professionals, such as physicians and clinicians, whose 
attendance was recognised by the Croatian Medical 
Chamber and Croatian Chamber of Medical Biochemists. 
The symposium was attended by 70 participants, 25 of 
whom came from Slovenia.
Our special thanks go to the general sponsors Kemomed 
and Illumina, for providing us with the resources necessary 
to organize this meeting. Kemomed was established in 1996 
and has constantly grown to provide a range of products 
from the fields of genetics, biotechnology, molecular 
biology, in vitro diagnostics, small lab inventory and 
equipment, and analytical columns. Kemomed is known 
for their high degree of proficiency, short delivery times, 
and excellent customer support. Illumina is the world’s 
leading provider of solutions in next generation sequencing.
We thank Arhiv for giving us the opportunity to publish 
abstracts and short CVs in this issue.
Zrinka Kovarik
on behalf of the Organising Committee
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The organisers and participants of the Symposium
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About the Speaker
Jernej Kovač defended his PhD in biochemistry and molecular biology in 2014 with a thesis researching the genetic 
background of oxidative stress mechanism genetics in the autism spectrum disorder. He participated in the development 
and establishment of the laboratory for cytogenetics at the Unit of Special Laboratory Diagnostics at University Children’s 
Hospital in Ljubljana and later switched to next generation sequencing and genetics of orphan diseases at the same 
institution. Currently, his main research interests are the genetics and epigenetics of obesity, hypercholesterolemia, insulin 
resistance and type 1 diabetes in the paediatric population, while his everyday work routine is focused on the genetic 
diagnostics of orphan diseases, using next-generation sequencing techniques.
Five years of NGS in a diagnostic setup: experience from 
the Unit of Special Laboratory Diagnostics at the 
University Children’s Hospital in Ljubljana
Jernej Kovač
Unit of Special Laboratory Diagnostics, University Children’s Hospital, University Medical Centre Ljubljana, Slovenia
The rapid technological advancement in the field of DNA/RNA sequencing technology in the last decade has boosted 
research in genomics and revolutionized the field of medical genetics. With the development of high-throughput DNA 
sequencers, next-generation sequencing (NGS) technology, and novel analytical algorithms, as well as the release of huge 
public databases of genetic variant allele frequency in the general population (GnomAD, ExAc, etc.), the paradigm of 
medical genetics has changed and shifted from diagnosis driven to a phenotype driven analytical approach. Moreover, 
the price to generate genomic data has significantly dropped and, consequently, the possibility of unbiased whole-genome 
sequencing to identify the disease-causing variants has become a reality. In the last five years since the introduction of 
NGS in the routine genetic diagnostic algorithms of the University Children’s Hospital in Ljubljana, major changes 
occurred regarding the analytical process, data handling and storage, as well as the development of novel applications 
using NGS. Processing more than 500 cases per year, ranging from genetic diagnostics of orphan diseases to the genetic 
analysis of more common diseases (hypercholesterolemia, obesity, hearing loss, etc.), the analytical burden to establish 
rapid sequencing, validated data analysis, and strict quality control became our primary concern. The lecture will try to 
illustrate the path from the sequencing of small targeted panels to whole human genomes and from basic capture technology 
to nanopore sequencing and the application of the NGS technology in a diagnostic and research setup. 
KEY WORDS: common diseases; genetic diagnostics; orphan diseases; technology
A20
How next-generation sequencing improves care of patients 
with genetic diseases
Aleš Maver, Alenka Hodžić, Gaber Bergant, Tanja Višnjar, and Borut Peterlin
Clinical Institute of Medical Genetics, University Medical Centre Ljubljana, Slovenia
The identification of a specific genetic cause in patients with suspected genetic diseases is essential to confirm the diagnosis 
and guide their medical management. It also enables the prediction of disease prognosis and occurrence in family members. 
Although the primary purpose of genetic testing in the past was in confirming a specific suspected diagnosis, recent 
advancements in sequencing technologies now permit a much broader survey of genetic causes in patients with suspected 
rare diseases. This is of particular importance, because a considerable fraction of patients does not have a specific diagnosis 
established prior to genetic testing and because the suspected diagnosis may be incorrect due to atypical or misleading 
presentation. At the Clinical Institute of Medical Genetics in Ljubljana, we have been performing the analysis of either 
the mendeliome, whole exome, or whole genome sequencing for diagnosing patients with suspected monogenic etiology 
since 2013. So far, we performed genetic testing using these approaches in over 2,000 patients, referred with a wide 
variety of disease categories. In all of these, we routinely examine the final diagnostic outcomes in their relation to the 
original diagnosis of referral and made a systematic follow-up on the diagnostic significance of untargeted approaches 
in a clinical setting. In the group of patients with a wide variety of disease categories, we reached a high overall diagnostic 
rate of 40.1 %. We have noted the emergence of new significant diagnostic outcomes of genetic testing in a considerable 
proportion of cases. This included the establishment of a specific diagnosis in a previously undiagnosed patient, which 
accounted for over 20 % of all positive findings. Furthermore, we have observed that in numerous positive cases (4.3 %), 
the original diagnosis was reclassified based on the result of genetic testing using exome or genome sequencing. In selected 
cases, we were also able to identify new disease genes and novel genotype to phenotype associations using these approaches. 
We will present a selection of cases, where the establishment or reclassification of a diagnosis proved to be of direct 
medical significance for patients. In conclusion, we present novel diagnostic outcomes associated with the implementation 
of exome and genome sequencing in routine genetic diagnostics. These outcomes shift the role of genetic testing from a 
confirmatory role to its utility in establishing diagnosis, reclassification, and expansion of existent gene-phenotype 
associations, with direct implications for medical management of patients. These observations also support early (albeit 
rational) use of genetic testing in diagnosing patients with a wide variety of disease categories. 
KEY WORDS: exome; genetic disease diagnostics; mendeliome; rare diseases
About the Speaker
Aleš Maver is currently leading the Centre for Mendelian Genomics (CMG) at the Clinical Institute of Medical 
Genetics in Ljubljana, in Professor Borut Peterlin’s team. CMG is one of the leading institutions in the region, providing 
next-generation sequencing based diagnostics and research, predominantly using exome and genome sequencing, as well 
as RNA sequencing. Their team has over five years of experience in diagnostic NGS with over 2000 exome/genome-based 
analyses performed so far. They reported the benefits of diagnostic exome sequencing in multiple disease categories and 
we published innovative approaches to analysing exome sequencing for maximum diagnostic yield. Recently, they reported 
identifications of several new genes for rare and complex human disorders, including novel findings in premature aging, 
epileptic encephalopathies, and multiple sclerosis.
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Genomics enabling the latest cancer breakthroughs in 
personalised medicine
Agnieszka Grybos-Gajniak
Illumina, Oxford, United Kingdom
An expanding next-generation sequencing (NGS) oncology portfolio is helping Illumina drive the revolution in cancer 
genomics. Our sample-to-data solutions deliver high-quality, reproducible results to speed the discovery and analysis of 
cancer-related variants and potentially transform the cancer care cycle. Immuno-oncology is an emerging field that has 
taken great strides in the fight against cancer, bolstered by a refined understanding of how tumours evade the natural 
immune response. Leading immuno-oncology researchers are leveraging next-generation sequencing to discover biomarkers 
and apply genomics to personalized immunotherapy. Research into the mechanisms tumours use to evade the immune 
response have led to promising therapeutic targets. These therapies boost the ability of the immune system to target cancer 
or limit the tumour’s ability to evade the natural immune response. Analysis of cell free DNA (cfDNA) is increasingly 
used to obtain information about the genetic state of normal and tumour tissues. Combining liquid biopsy with NGS 
technology provides a non-invasive method to analyse numerous cancer-related genes in a single assay. Find out how our 
products are helping propel progress in personalized oncology.
KEY WORDS: genetic diseases; immune response; immuno-oncology; next-generation sequencing
About the Speaker
Agnieszka Grybos-Gajniak is currently a Senior Clinical Specialist Field Application Scientist at Illumina. She has 
been responsible for supporting oncology applications across EMEA for the past two years. The products she supports 
include AmpliSeq™ for Illumina® as well as TruSight® Oncology portfolio. She has received her master’s degree in 
biotechnology from the Jagiellonian University in Cracow, Poland (Faculty of Biochemistry, Biophysics and Biotechnology). 
Her research focused on the influence of oxidative stress on etoposide-induced DNA damage in human leukaemia cells. 
In her previous commercial roles she has been involved in development and application support of various assays used 
in oncology field including fluorescence in situ hybridisation (FISH), microarrays (aCGH), and next generation sequencing.
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About the Speaker
Irena Drmić Hofman is a full Professor of Biochemistry and Molecular Biology at the University of Split (School 
of Medicine) and a member of the Laboratory for Molecular Diagnostics at the University Hospital Centre Split. She 
received her undergraduate education from the University of Split and her master’s and doctoral degrees from the University 
of Zagreb. Study periods abroad include University of Verona, Italy, and University of Münster, Germany. She started 
working as a forensic geneticist at the Department of Pathology, Forensic Medicine and Cytology of the University 
Hospital Centre Split in 1992. Since 2000, she has been a senior researcher at the Laboratory for clinical molecular 
genetics. Professor Drmić Hofman’s main research interests are the genomics and proteomics of tumours and risk factors. 
She (co)authored more than 40 papers in peer reviewed journals, as well as several textbook chapters and is a reviewer 
for several international journals. She is a member of The Board of Croatian Society for Human Genetics and Chair of 
the Split Branch of the HDBMB.
NGS-based BRCA1,2 mutation testing of high- grade 
serous ovarian carcinoma
Irena Drmić Hofman1,2, Sendi Kuret1, and Snježana Tomić1,2
University Hospital Centre1, University of Split, School of Medicine2, Split, Croatia
Technological advances in the development of sequencing techniques have led to the increasing application of next-
generation sequencing (NGS) in understanding the nature of many diseases and their improved treatment, especially for 
malignant diseases. An increasing amount of data shows that high-grade (HG) serous ovarian cancer patients carrying 
BRCA1 and BRCA2 mutations – both somatic and germline – experience a survival advantage and are more sensitive to 
agents such as platinum and PARP inhibitors. In the period 2016-2018 we analysed mutations of BRCA1,2 genes in 
patients with HG- serous ovarian cancer, treated at the University Hospital Centre Split (n=80). Genomic DNA was 
isolated from blood, a library was prepared using the TruSeq Custom Amplicon Low Input Library Prep Kit and analysed 
on a MiniSeq Instrument (both Illumina, San Diego, CA, USA). Deleterious germline mutations were identified in 21 
patients (26 %), 13 in the BRCA1 and 8 in the BRCA2 gene. The most common mutations in the BRCA1 gene were 
c.5266dupC (p.Gln1756ProfsV74) and c.843_846delCTCA (p.Ser282Tyrfs), found in 9 (42.85 %) and 2 patients, 
respectively. The most common mutation in the BRCA2 gene was c.9371A>T (p.Asn3124Ile), found in 2 patients (9.5 %). 
Numerous advantages of the NGS approach have been demonstrated, since it has proven to be highly sensitive, as have 
specific methods for BRCA mutation analysis in patients with HG-serous ovarian cancer, since it allows the simultaneous 
screening of multiple genes, reduces turnaround time of analysis, and requires a very low input of DNA. 
KEY WORDS: genomics; malignant diseases; next generation sequencing; sensitivity of method
A23 ABSTRACTSArh Hig Rada Toksikol 2018;69:A18-A23
Identification of Lowe syndrome in a child with a novel 
mutation in the OCRL gene, using whole exome 
sequencing
Robert Belužić, Filip Rokić, and Oliver Vugrek
Laboratory for Advanced Genomics, Ruđer Bošković Institute, Zagreb, Croatia
Lowe syndrome is a rare X-linked recessive hereditary disease caused by mutations of the OCRL gene, which encodes 
an inositol polyphosphate- 5-phosphatase. Congenital cataracts, psychomotor retardation, and proximal tubulopathy 
clinically characterize the disease. At 12 days of age, the patient presented hypotonia and congenital bilateral cataracts. 
Metabolic analysis appeared normal and the child was released with recommendations for neurodevelopmental habilitation. 
At the age of 12 months, abdominal ultrasonography showed morphology of the patient’s kidneys, urine, and blood levels 
of creatinine were within regular limits. However, over the next 36 months, the clinical picture deteriorated and the patient 
presented highly elevated values for creatine kinase, aminoaciduria, and severe psychomotor retardation. Lowe syndrome 
was confirmed at the age of 52 months using Whole-Exome-Sequencing (WES), showing a novel mutation in the OCRL 
gene, introducing a nonsense mutation in exon 10 at amino acid position 215 (c.643C>T / p.Gln215*). The mother of the 
patient was a heterozygous carrier of the respective mutation. In view of the clinical data, in particular kidney morphology 
and metabolic values, our findings indicate phenotypic variability in patients with Lowe syndrome, which made a precise 
diagnosis challenging and time consuming. 
KEY WORDS: bilateral cataract; Fanconi syndrome; genomics; glaucoma; hypophosphataemia; psychomotor retardation; 
WES
About the Speaker
Oliver Vugrek is a molecular biologist with many years of experience in genetics of rare diseases. He graduated in 
Biology at the Albert Einstein University in Ulm, Germany. He was a PhD fellow at the Max Planck Institute for Cell 
Biology from 1992 to 1995 and received his PhD in 1995 at the Karl Ruprechts University in Heidelberg, Germany. He 
spent two years at Australia’s National University (ANU) in Canberra as a postdoctoral fellow. He has been employed at 
the Ruđer Bošković Institute since 1999 and is currently head of the Laboratory for Advanced Genomics. Dr Vugrek has 
led significant EU projects, including the FP7 project InnoMol, the largest Natural Sciences project ever conducted in 
Croatia, bringing genomics research at the Ruđer Bošković Institute to a new level. His research interests are devoted to 
the introduction of new technologies for advanced DNA sequencing and analysis of genetic disorders. Oliver Vugrek is 
an active member of the HDBMB and member of the Federation of European Biochemistry Societies (FEBS) Fellowships 
Committee (2017-2010).
